CARLSBAD, Calif., May 18 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (Nasdaq: IMNR), a biopharmaceutical company developing immune-
based therapies (IBT) for HIV and multiple sclerosis (MS), today announced
that David C. Mitchell has joined the company as Executive Director,
Regulatory Affairs. Mr. Mitchell assumes a new company position and will be
responsible for all aspects of regulatory affairs including those related to
the world-wide clinical development programs for both HIV and MS, licensing
and marketing registration.
"The combination of David's experience in biologics as well as FDA
negotiation and submission is a tremendous asset to The Immune Response
Corporation," said John N. Bonfiglio Ph.D., Chief Executive Officer of The
Immune Response Corporation. "We are delighted that David is joining us at
this time as we embark on an expanded clinical program for both HIV and MS and
move towards commercialization. He will be a great value to the Company as we
move forward."
He joins from Biogen Idec, Inc. (Nasdaq: BIIB) where he was Director of
Regulatory Affairs. He provided leadership in the development and
implementation of innovative and compliant regulatory strategies in support of
drug candidates and marketed products, including the successful launch of
Zevalin(R) for the treatment of non-Hodgkin's lymphoma. Prior to Biogen Idec,
Mr. Mitchell served as Director, Regulatory Affairs and QA/QC at Maxia
Pharmaceuticals, Inc. where he had full responsibility for regulatory and
quality functions in the development of four product candidates in oncologic
and metabolic indications. Mr. Mitchell has also held regulatory positions
with Anergen, Inc. (now a part of Corixa), Biometric Research Institute, Inc.,
Upjohn, Bayer and Solvay Pharmaceuticals.
"David's employment at The Immune Response Corporation is the latest step
in building a world-class organization capable of handling multiple products
in a highly regulated environment. We expect that this addition will help us
to meet all of our regulatory and clinical goals in the next several years,"
concluded Dr. Bonfiglio.
Mr. Mitchell graduated with a Bachelor of Science degree in chemistry from
Mississippi College in Clinton, MS. He is a member of the American Chemical
Society (ACS), the Drug Information Association (DIA) and the Regulatory
Affairs Professionals Society (RAPS).
About The Immune Response Corporation
The Immune Response Corporation (Nasdaq: IMNR) is developing immune-based
therapies (IBT) for HIV and multiple sclerosis. The Company's HIV products
are based on its patented whole-killed virus technology, co-invented by
Company founder, Dr. Jonas Salk, to stimulate HIV immune responses.
REMUNE(R), currently in Phase II, is being developed as a treatment for people
with HIV. The Company has initiated development of a new IBT, IR103, which
incorporates a second-generation immunostimulatory oligonucleotide adjuvant.
The Immune Response Corporation is also developing an IBT for multiple
sclerosis (MS), NeuroVax(TM), which is currently in Phase II and has shown
potential therapeutic value for this difficult-to-treat disease.
Please visit The Immune Response Corporation on the World Wide Web at
http://www.imnr.com
This news release contains forward-looking statements. Forward-looking
statements are often signaled by forms of words such as should, could, will,
might, plan, projection, forecast, expect, guidance, potential and developing.
Actual results could vary materially from those expected due to a variety of
risk factors, including whether the Company will continue as a going concern
and successfully raise proceeds from financing activities sufficient to fund
operations and additional clinical trials of REMUNE(R), NeuroVax(TM) or IR103,
the uncertainty of successful completion of any such clinical trials, the fact
that the Company has not succeeded in commercializing any drug, the risk that
REMUNE(R), NeuroVax(TM) or IR103 might not prove to be effective as either a
therapeutic or preventive vaccine, whether future trials will be conducted and
whether the results of such trials will coincide with the results of
REMUNE(R), NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical
trials. These risks, among others, are set forth in The Immune Response
Corporation's SEC filings including, but not limited to, its Annual Report on
Form 10-K for the year ended December 31, 2003, and any subsequent Quarterly
Reports on Form 10-Q. The Company undertakes no obligation to update the
results of these forward-looking statements to reflect events or circumstances
after today or to reflect the occurrence of unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation.
Zevalin(R) is a registered trademark of Biogen Idec, Inc.
MEDIA CONTACT:
Laura Silver, Sam Brown Inc. Corporate Communications
310-551-9940
silver@sambrown.com
INVESTOR RELATIONS CONTACT:
Kathy Waller, Financial Relations Board
312-266-7800
kwaller@financialrelationsboard.com
AT THE COMPANY:
Michael K. Green, Chief Financial Officer
760-431-7080
info@imnr.com.
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
CONTACT:
media, Laura Silver of Sam Brown Inc.
Corporate Communications, +1-310-551-9940, silver@sambrown.com,
or investor relations, Kathy Waller of Financial Relations Board,
+1-312-266-7800, kwaller@financialrelationsboard.com, both for
The Immune Response Corporation; or Michael K. Green, Chief
Financial Officer of The Immune Response Corporation,
+1-760-431-7080, info@imnr.com
|
